

# CURRICULUM VITAE

**NAME** : Mircea DEDIU

**INSTITUTION** : NORD Provita Medical Gorup

Bld Dimitrie Pompeiu nr 9-9A, 020335, Bucharest, Romania

## PRESENT POSITION

- Chief of Medical Oncology Department

## FORMER CHIEF OF MEDICAL ONCOLOGY DEPARMENT ( SINCE 2002)

- Institute of Oncology Bucharest
- Sandor Cancer Center

## MEDICAL DEGREES AND ACADEMIC TITLES

- Correspondent member of The Romanian Academy of Medical Sciences
- medical oncology senior consultant
- PhD
- Senior scientific researcher

## INTERNATIONAL RECOGNITION

- **Certification of professional level at European standards :**
  - *Confirmed by ESMO scientific Committee as Certified member* of European Society of Medical Oncology after successful examination, Hamburg ,20 Oct 2000.
- **Full member of international medical societies**
  - American Society of Clinical Oncology : membership ID 34465
  - European Society of Medical Oncology : member ID 1606
  - International Association for the Study of Lung Cancer : membership ID 234133
  - European Organization For Research and Treatment of Cancer : Inst 6052
  -
- **International board position**
  - Romanian National Representative at European Society of Medical Oncology 2004-2011
  - Member of Board of Directors in Balkan Union of Oncology 2000-2012
- **Editorial board member : International journals**
  - Journal of BUON, Official Journal of Balkan Union of Oncology, indexed PubMed, Zebrinis Medical Publications, Athens, Greece, ISSN 1107-0625
  - Memo –magazine of European medical oncology- Official journal of the Central European cooperative Oncology Group (CECOG), SpringerWien new York Wien, ISSN 1865-5041
  - FramingHam on lung cancer, Framingham Online, Amalialaan 126 G, 3743 KJ Baarn , Netherlands; <http://www.canceronlinejournal.com>

## FOREIGN LANGUAGES (FLUENT)

- English
- French

## Publications in international journals

### Report from Web of Science Thompson Reuters 2022

#### Publication Metrics

Citation counts are from Web of Science Core Collection.

**74**

Publications in  
Web of Science


**6,782**

Sum of Times  
Cited

**16**

H-Index

#### Times Cited and Publications Over Time



## FULL TEXT PAPERS

1. Maximilian J. Hochmair, Mojca Unk, Jelena Spasic, Timur Cerić, Assia Konsoulova, **Mircea Dediu**, Krisztina Bogos, Alinta Hegmane, Kersti Oselin, Marko Stojiljkovic, Tina Roblek and Mark Jakopovic. Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability. *BMC Proc* **18** (Suppl 3), 2 (2024). <https://doi.org/10.1186/s12919-023-00287-6>
2. The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the Lung. *Curr. Oncol.* 2023, 30, 7218–7228. Buium, C.; Negru, S.; Ionescu, D.N.; **Dediu, M.**
3. Perspectives for Cancer Care and Research in Central and Eastern Europe  
Christoph Carl Zielinski, Tanja Cufer, Bostjan Seruga, Jacek Jassem, **Mircea Dediu**, Christiane Thallinger. *Oncol Res Treat* 2022 Dec 2. doi: 10.1159/000528487. Online ahead of print .PMID: 36463856 DOI: 10.1159/000528487
4. Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)  
Urška Janžič, Nina Turnšek, **Mircea Dediu**, Ivan Shterev Donev, Roxana Lupu, Gabriela Teodorescu, Tudor E. Ciuleanu and Adam Pluzanski. *Curr Oncol* 2022; 29:5833-5845
5. A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. **Mircea Dediu**, Christoph Zielinski. *Breast Care (Basel)* 2020 ;15(1):67-71.
6. Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer". **Mircea Dediu**, Christoph Zielinski. *Breast Care (Basel)* 2020 ;15(3):314-316.
7. Current trends in Small Cell Lung Cancer management – ASCO 2019 update. **M. Dediu**. *Magazine of European Medical Oncology (MEMO)* 2019; 12: 297–300.
8. Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer  
Yonesaka, K ; Hirotsu, K ; von Pawel, J ; **Dediu, M** ; Chen, SQ ; Copigneaux, C  
Nakagawa, K .  
*LUNG CANCER* 2017, 105; 1-6
9. Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in change  
**Mircea Dediu**, Florentina Bratu, Mihaela Amarandei, Eniko Fejer  
*JBOUN* 2016; 21:1379-1382
10. The effect of necitumumab in combination with gemcitabine plus cisplatin on tolerability and on quality of life: results from the phase III SQUIRE trial  
Martin Reck, MD, PhD; Mark A. Socinski, MD; Alexander Luft, MD; Aleksandra Szczęśna, MD; **Mircea Dediu**, MD; Rodryg Ramlau, MD, PhD; György Losonczy, MD, DSc, Olivier Molinier, MD; Christian Schumann, MD, PhD; Richard Gralla, MD; Philip Bonomi, MD; Jacqueline Brown, PhD; Victoria Soldatenkova, MS; Nadia Chouaki, MD; Coleman Obasaju, MD, PhD; Patrick Peterson, PhD; Nick Thatcher, MD, PhD,

11. Nectin-4 antibody plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial  
Prof Nick Thatcher, FRCPa, Fred R Hirsch, MD, Alexander V Luft, MD, Aleksandra Szczesna, MD, Prof Tudor E Ciuleanu, MD, **Mircea Dediu**, MD, Prof Rodryg Ramlau, MD, Rinat K Galiulin, MD, Beatrix Bálint, MD, Prof György Losonczy, MD, Andrzej Kazarnowicz, MD, Keunchil Park, MD, Prof Christian Schumann, MD, Martin Reck, MD, Henrik Depenbrock, MD, Shivani Nanda, MS, Anamarija Kruljac-Letunic, PhD, Raffael Kurek, MD, Luis Paz-Ares, MD, Prof Mark A Socinski, MDs, *Lancet Oncol 2015;16:763-774*
12. Nectin-4 antibody plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study  
Luis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, Jürgen R Fischer, Joachim von Pawel, Mariano Provencio, Andrzej Kazarnowicz, György Losonczy, Gilberto de Castro Jr, Aleksandra Szczesna, Lucio Crino, Martin Reck, Rodryg Ramlau, Ernst Ulsperger, Christian Schumann, Jose Elias A Miziara, Álvaro E Lessa, **Mircea Dediu**, Beatrix Bálint, Henrik Depenbrock, Victoria Soldatenkova, Raffael Kurek, Fred R Hirsch, Nick Thatcher, *Lancet Oncol 2015; 16: 328-337*
13. Efficacy and Safety of Maintenance Pemetrexed in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer Following Pemetrexed plus Cisplatin Induction Treatment: A Cross-trial Comparison of Two Phase III Trials  
G.V. Scagliotti, C. Gridelli, F. de Marinis, M. Thomas, **M. Dediu**, J.-L. Pujol, C. Manegold, B. San Antonio, P.M. Peterson, W. John, N. Chouaki, C. Visseren-Grul, L.G. Paz-Ares  
*Lung Cancer 2014; 85: 408-414*
14. Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer.  
J.L. Pujol, L. Paz-Ares, F. de Marinis, **M. Dediu**, M. Thomas, P. Bidoli, J. Corral, B. San Antonio, N. Chouaki, W. John, A. Zimmermann, C.M. Visseren-Grul, C. Gridelli  
*Clinical Lung Cancer 2014; 15:418-425*
15. Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer  
Joachim von Pawel, Jimmie H. Harvey, David R. Spigel, **Mircea Dediu**, Martin Reck, Cristina L. Cebotaru, Robin C. Humphreys, Matthew J. Gribbin, Norma Lynn Fox, D. Ross Camidge  
*Clinical Lung Cancer 2014, Vol. 15, No. 3, 188-96*
16. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer  
Luis G. Paz-Ares, Filippo de Marinis, **Mircea Dediu**, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck, Jesu's Corral, Symantha Melemed, William John, Nadia Chouaki, Annamaria H. Zimmermann, Carla Visseren-Grul, and Cesare Gridelli  
*J Clin Oncol 2013; 31: 2895-2902*

17. An international survey of practice patterns and difficulties in cancer pain management in Southeastern Europe: A Turkish & Balkan Oncology Group common initiative.  
Ajlan Atasoy, Gordana Bogdanovic, Archil Aladashvili, Zeljka Cvijetic,  
**Mircea Dediu**, Nada Cicmil-Saric, Armen Nersesyan, Athanasios Athanasiou, Nazim Serdar Turhal  
*JBUON 2013; 18(4): 1082-1087*
18. A COST-EFFECTIVENESS ANALYSES OF USING SUNITINIB (SU) IN FIRST LINE OF METASTATIC RENAL CANCER IN ROMANIAN JURISDICTION  
Berghea, F (Berghea, F.) [ 1 ] ; Skoupa, J (Skoupa, J.) [ 2 ] ; Ciuleanu, T (Ciuleanu, T.) [ 3 ] ; Miron, L (Miron, L.) [ 4 ] ; Stanculeanu, DL (Stanculeanu, D. L.) [ 5 ] ; Jinga, D (Jinga, D.) [ 6 ] ; Dediu, M (Dediu, M.) [ 5 ] ; Mateescu, DN (Mateescu, D. N.) [ 7 ] ; Hajek, P (Hajek, P.) [ 8 ] ; Bradatan, B (Bradatan, B.) [ 9 ] ; Xuan, J (Xuan, J.) [ 10 ]  
VALUE IN HEALTH 2013; Volume: 16 Issue: 7 Pages: A411-A412
19. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial  
  
Luis Paz-Ares, Filippo de Marinis, **Mircea Dediu**, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck, Jesús Corral, Symantha Melemed, William John, Nadia Chouaki, Annamaria H Zimmermann, Carla Visseren-Grul, Cesare Gridelli  
*Lancet Oncology 2012, 13: 247-255*
20. International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1  
Giorgio V. Scagliotti, Ihor Vynnychenko, Yukito Ichinose, Kaoru Kubota, Fiona Blackhall, Robert Pirker, Rinat Galiulin, Tudor-Eliade Ciuleanu, Oleksandr Sydorenko, **Mircea Dediu**, Zsolt Papai-Szekely, Natividad Martinez Banaclocha, Sheryl McCoy, Bin Yao, Yong-jiang Hei, Francesco Galimi and David R. Spigel  
*J Clin Oncol 2012; 30:2829-2836*
21. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: An analysis of 112 consecutively treated patients.  
**M. Dediu**, O. Ion, R. Ion, A. Alexandru, D. Median, C. Gal, T. Horvat, C. Motas, N. Motas.  
*J BUON Vol. 17, No 2, 2012, pp 317-322.*
22. Controversies in the management of advanced non-small cell lung cancer: maintenance therapy"  
**M. Dediu**. *J BUON 2011; 16: 431-433.*
23. Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study  
Glenwood D. Goss, Andrew Arnold, Frances A. Shepherd, **Mircea Dediu**, Tudor-Eliade Ciuleanu, David Fenton, Mauro Zukin, David Walde, Francis Laberge, Mark D. Vincent, Peter M. Ellis, Scott A. Laurie, Keyue Ding, Eliot Frymire, Isabelle Gauthier, Natasha B. Leighl, Cheryl Ho, Jonathan Noble, Christopher W. Lee, Lesley Seymour  
*J Clin Oncol 2010 ; 1: 49-55.*

24. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor inhibitor cediranib: NCIC Clinical Trials Group Study BR 24.  
R. Godwin, K. Ding, L. Seymour, A. Lemaitre, A. Arnold, F.A. Shepherd, **M. Dediu**, T. Ciuleanu, D. Fenton, M. Zukin et al.  
*Ann Oncol* 2010 ; 21:2220-2226
25. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: Results of a prospective observational study.  
**Dediu M**, Crisan E, Radut M, Tarlea A, Median D, Alexandru A, Vremes G, Gal C.  
*Lung Cancer*. 2009; 63: 271-276.
26. Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor-positive breast cancer patients: upfront or sequential?  
**Dediu, M.**; Median, D.; Alexandru, A.; et al.  
*Journal of BUON* 2009; 14: 375-379
27. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.  
Roila F, Rolski J, Ramlau R, **Dediu M**, Russo MW, Bandekar RR, Grunberg SM.  
*Ann Oncol*. 2009; 20: 1867-1873
28. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.  
Gatzemeier U, Ciuleanu T, **Dediu M**, Ganea-Motan E, Lubenau H, Del Giglio A.  
*J Thorac Oncol*. 2009 Jun;4(6):736-40.
29. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.  
**M. Dediu**, O. Ion, R. Ion, C. Gal, D. Median, M. Gongu.  
*Journal of BUON* 2009; 14( Suppl 1): S159-S164.
30. Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer.  
Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, **Dediu M**, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N.  
*J Clin Oncol*. 2009 ; 1: 4787-4792.
31. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Leśniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, **Dediu M**, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ.  
*J Thorac Oncol*. 2008 Jun;3(6):623-30.
32. Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.  
**M. Dediu**, D. Median, A. Alexandru, G. Vremes, C. Gal.

*Journal of BUON 2007; 12 ( Suppl 1) : S137-S149.*

33. Compliance with adjuvant chemotherapy in non-small cell lung cancer. The experience of a single institution evaluating a cohort of 365 patients.  
**M. Dediu**, A. Alexandru, D. Median, R. Anghel, P. Iorga, M. Movanu.  
*Journal of BUON 2006; 11: 425-432.*
34. Adjuvant chemotherapy for radically resected non-small cell lung cancer. A retrospective analysis of 311 consecutively treated patients.  
**M. Dediu**, T. Horvat, A. Tarlea, R. Anghel, I. Cordos, G. Miron, P. Iorga, A. Alexandru, C. Nistor, C. Grozavu, C. Savu.  
*Lung Cancer 2005 ; 47 : 93-101.*
35. Erlotinib in previously treated non-small-cell lung cancer.  
Shepherd F, Rodrigues P, Ciuleeanu TT, Tan E, Hirsh V, Sumitra T, Campos D, Maloekoonpiroj S, Smyle M, Martins R, van Kooten M, **Dediu M**, et al.  
*The New England Journal of Medicine, 2005; 353 :123-132.*
36. Anthracycline pretreated patients: who is who in the chemotherapy choice of relapsed breast cancer ?.  
**M. Dediu**, A. Alexandru, D. Median  
*Journal of BUON 2005; 10 : 323-328.*
37. Chemotherapy for resectable non-small cell lung cancer. It's time for a change in the current paradigm.  
**M. Dediu**, A. Alexandru, D. Median, G. Vremes. Athanasios E. Athanassiou editor. Lung cancer: Current Status and Perspectives.  
*A Special edition of Journal of BUON 2005, Sept; 61- 88. ISSN 1107-0625.*
38. Split course radiation with concurrent Vinorelbine (NVB) and Cisplatin (CDDP) in locally advanced Non-Small Cell Lung Cancer (NSCLC). A phase II study  
**M. Dediu**, A. Tarlea, P. Iorga, M. Radut, A. Alexandru, G. Miron, C. Cornila.  
*Journal of BUON 2004; 9: 167-172.*
39. Should we discard vinorelbine plus cisplatin from the first line treatment of non-small cell lung cancer ? ( Letter to the editor )  
**M. Dediu.**  
*Journal of Clinical Oncology 2004; 22 : 1345- 1347.*
40. Controversies in the management of non-small cell lung cancer : chemotherapy around surgery; pre or post-operative ?.  
**M. Dediu.**  
*Journal of BUON 2003; 8:97-100.*
41. Combined modality treatment for stage III non-small cell lung cancer : the performance , the actors and the backstage.  
**M. Dediu**  
*Journal of BUON 7: 85-86, 2002.*
42. Is long term gemcitabine useful in small cell lung cancer? (Letter to the Editor)  
**M. Dediu.**  
*Lung Cancer 2002 ;36 : 217-218.*

43. A comparative evaluation of surgery followed by adjuvant chemo-radiation versus neoadjuvant chemotherapy followed by concurrent chemo-radiation, for stage III A non-small cell lung cancer (NSCLC). A multi institutional study.  
**M. Dediu**, Teodor Horvat, Alin Tarlea, Emilia Crisan, Mirela Movanu, Alexandru Nicodin, Polixenia Iorga, Maria Radut  
*Journal of BUON Vol 6, No 1, pp : 29-35, 2001.*
44. High dose cisplatin and concurrent radiation therapy in stage III A non-small cell lung cancer.  
**M. Dediu**, A. Tarlea, R. Anghel, M. Radut, E. Crisan.  
*Journal of B.U.ON. ( Official Journal of the Balkan Union of Oncology) Volume 5, No 1, pp 17-24, 2000.*
45. Second look surgery in ovarian cancer : controversy between theoretical justification and practical results.  
**M. Dediu** , V. Tarlea, M. Movanu.  
*Journal of B.U.ON. ( Official Journal of the Balkan Union of Oncology) Volume 4, No 2 ,pp :199-202, 1999.*
46. Current trends in small cell lung cancer management—  
ASCO 2019 update. MEMO 2019
47. ESMO 2017 -my personal highlights. Kieseewetter B, Dediu M, Bartsch R. . memo –  
Magazine of European Medical Oncology 2018; 11: 77-79
48. My personal highlights of ESMO 2016  
Dediu, M; Gerger,; Zojer, N ; Bartsch, R  
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY Feb 2017; 10:46-47
49. Maintenance therapy for patients with advanced non-small cell lung cancer : fact or myth?  
**M. Dediu.**  
Editorial article, Magazine of European Medical Oncology ( memo) 2011; 4: 1-2.
50. Adjuvant chemotherapy in stage IB NSCLC: implication of the new TNM staging system.  
**M. Dediu.** Magazine of European Medical Oncology ( memo) 2011; 4: 16-18.
51. Non-small cell lung cancer. (ASCO update)  
**M. Dediu**, W. Hilbe  
Magazine of European Medical Oncology(memo) 2008; 1:247-251.
52. Adjuvant chemotherapy in stage IB non-small cell lung cancer : if, when, how?  
**M. Dediu.**  
Magazine of European Medical Oncology (memo) 2008; 1: 61-65.
53. Pemetrexed in non-small-cell lung cancer  
**Mircea Dediu** , Aurelia Alexandru , Florentina Bratu  
Lung Cancer Management, June 2014, Vol. 3, No. 3, Pages 273-285.
54. Management of patients with NSCLC in progression after 1<sup>st</sup> line chemotherapy  
**M. Dediu**  
Endoscopic Review( Journal of Slovene Association of endoscopic Surgery and Society of Gastroenterologic Endoscopy) 2008; 13: 29-34.

55. "Vitamin B-12 forbidden for cancer patients ": a dogma with validity term expired.  
**M. Dediu** British Medical Journal (BMJ)(Romanian language edition), Nr 2, Volume 6;  
pp :86,1999.

## Oral presentations in international meetings

1. Increasing Survival in Stage III NSCLC: Optimizing Care. M. Dediu. CEE Academy Lung Cancer. Vienna ; 15-16 Nov 2019.
2. Systemic therapy of MPM. M. Dediu . Multidisciplinary refresher course on Thoracic Malignancies April 5-6, 2019, Brdo, Slovenia.
3. Biochemical recurrence of localized prostate cancer. M. Dediu. 4th South East European Prostate Cancer Forum. 21 - 23 MARCH 2019, Novotel Wien Hauptbahnhof, Vienna, Austria
4. Systemic therapy of Malignant Pleural Mesothelioma. M. Dediu. CECOG Academy , 2018; feb 18, Brdo, Slovenia
5. Current management of inoperable stage III NSCLC.M. Dediu. CECOG Academy , 2018; feb 18, Brdo, Slovenia.
6. New concepts in the era of Immune Check point inhibitors (PACIFIC).M. Dediu. CECOG Academy, Lung Cancer, 2-3 November 2017, Vienna
7. Unsantifying the Sanctuary : challenges and opportunities with brain metastases . M. Dediu. CECOG Academy, Lung Cancer, 2-3 November 2017, Vienna.
8. Current status of docetaxel in advanced hormone sensitive prostate cancer.  
M. Dediu  
2<sup>nd</sup> South East European Prostate Cancer Forum, 23-24 Feb 2017, Zagreb, Croatia
9. How to read clinical trials-take home messages for the clinician.  
M. Dediu  
Central European Initiative against Lung Cancer. 5<sup>th</sup> Expert Forum. 01 April 2017, Prague, Czech, Republic
10. Current status and further perspectives in the treatment of EGFR mutant non-small cell lung cancer.  
M. Dediu  
The 10th Annual World Cancer Congress, 19-21 may 2017, Barcelona, Spain,
11. Second line treatment in advanced NSCLC.  
**M. Dediu**  
The 2015 Controlling Cancer Summit 12<sup>th</sup>-14<sup>th</sup> May 2015 London, UK
12. Case Discussions: Optimal Diagnosis and Treatment of ALK+ NSCLC Patients  
**M. Dediu .**  
14th Central European Lung Cancer Conference. Vienna ,29.11.-02.12.2014.
13. LUME-Lung 1/ Nintedanib update  
**M. Dediu.**

14th Central European Lung Cancer Conference. Vienna ,29.11.-02.12.2014

14. "LUME Lung 2 – exploratory finding of a clinical biomarker which was prospectively investigated and validated with positive Lume Lung 1 results  
**M. Dediu.**  
Central European Initiative against lung cancer. Expert Forum . Vienna.16- 17.03.2014
15. "How to diagnose and manage NSCLC with the new drugs" - an interactive session: To continue or not to continue, that is the question?  
**M.Dediu**  
European Respiratory Society Congress, Vienna, 2 September 2012
16. Impact of adjuvant chemotherapy in stage IB non-small cell lung cancer. An analysis of 112 consecutively treated patients.  
**M. Dediu**, 12 Central-European Lung Cancer Conference, Budapest, Hungary, 2-4 December 2010
17. Controversies around the use of the monoclonal antibodies in the treatment of advanced non-small cell lung cancer  
**M. Dediu**, 3rd BSO Seminar, Volos, Greece, 10-12 September 2009.
18. Breast Cancer: Adjuvant Endocrine Therapy of the Future.  
**M. Dediu**, 7th Congress of the Balkan Union of Oncology; Kusadasi, Turkey, 15-19 October 2008
19. MANAGEMENT OF PATIENTS WITH NSCLC IN PROGRESSION AFTER 1ST LINE CHEMOTHERAPY  
**M. Dediu**, 11th CELCC, Ljubljana, Slovenia; 12-14 June 2008,Ljubljana,Slovenia
20. EGFR-tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib  
**M. Dediu**, Balkan School Of Oncology 2, Volos, Greece 6-8 September 2007
21. The tyrosine kinase inhibitors: a new therapeutic avenue in non-small cell lung cancer  
**M. Dediu**, 6th CONGRESS OF THE BALKAN UNION OF ONCOLOGY, Sofia, Bulgaria, 13-16 September 2006
22. Confounding factors influencing patients' compliance with adjuvant chemotherapy (CT) in reconstruct non-small cell lung cancer (NSCLC). A multivariate analysis  
**M. Dediu**, 6th CONGRESS OF THE BALKAN UNION OF ONCOLOGY, Sofia, Bulgaria, 13-16 September 2006
23. Atelectasis as a good prognostic factor for locally advanced non-small cell lung cancer  
**M. Dediu**, 6th CONGRESS OF THE BALKAN UNION OF ONCOLOGY, Sofia, Bulgaria, 13-16 September 2006
24. Patient Outcome Following Adjuvant Chemotherapy (CT) in Completely Resected, Stage I-IIIB, Non-Small Cell Lung Cancer (NSCLC)  
**M. Dediu**, 10<sup>th</sup> Central European Lung Cancer Conference, Prague, Czech Republic, 10 March 2006
25. Chemotherapy for resectable non-small cell lung cancer. It's time for a change in the current paradigm.  
**M. Dediu**, First educational course of BSO, Volos, Greece, 16-17 September 2005
26. Adjuvant and Neoadjuvant Chemotherapy in NSCLC

- M. Dediu** European Lung Cancer Experts Board, Vienna, Austria, 24-25 November 2005
27. Cisplatin based adjuvant chemotherapy in completely resected non-small cell lung cancer.(Oral presentation OP98).  
**M. Dediu**, T. Horvat, A. Tarlea, R. Anghel, G. Miron. Fifth Congress of The Balkan Union of Oncology (BUON), 14-17 October ,2004, Belgrade, Serbia and Montenegro.
28. Adjuvant chemotherapy in the non-small cell lung cancer (Oral presentation).  
**M. Dediu**. Symposium : New approaches in the diagnosis and treatment of non-small cell lung cancer. Fifth Congress of The Balkan Union of Oncology (BUON), 14-17 October ,2004, Belgrade, Serbia and Montenegro. Proceedings/educational book. Balkan union of oncology. C-129.
29. Chemotherapy around surgery: Pre or Post-operative  
**M. Dediu**, Congress of the Balkan Union of Oncology nov.22-23, 2002 Athens
30. Current situation of oncology in Romania  
M. Dediu, Congress of the Balkan Union of Oncology nov.22-23, 2002 Athens

#### **ABSTRACTS – ISI Indexed Journals**

1. THE EFFECT OF NECITUMUMAB IN COMBINATION WITH GEMCITABINECISPLATIN ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND TOLERABILITY: SQUIRE TRIAL PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-EXPRESSING SQUAMOUS NSCLC TUMOURS  
Reck, M ; Socinski, M ; Szczesna, A ; Dediu, M; Ramlau, R ; Losonczy, G ; Molinier, O ; Schumann, C ; Brown, J ; Soldatenkova, V ] ; Chouaki, N ; Thatcher, N ; Luft, A  
VALUE IN HEALTH 2016, 19: A748-A749
2. Soluble heregulin, HER3 ligand, to predict the efficacy of anti-HER3 antibody patritumab combination with erlotinib in randomized phase II study, HERALD, for non-small cell lung cancer.  
Yonesaka, K (Yonesaka, Kimio); Hirotani, K (Hirotani, Kenji); Von Pawel, J (Von Pawel, Joachim); Dediu, M (Dediu, Mircea); Chen, SQ (Chen, Shuquan); Copigneaux, C (Copigneaux, Catherine); Nakagawa, K (Nakagawa, Kazuhiko)  
JOURNAL OF CLINICAL ONCOLOGY 2016; 34: Supplement: S; Abstract no: 9071
3. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)  
Thatcher, N (Thatcher, Nick); Hirsch, FR (Hirsch, Fred R.); Szczesna, A (Szczesna, Aleksandra); Ciuleanu, TE (Ciuleanu, Tudor-Eliade); Szafranski, W (Szafranski, Wojciech); Dediu, M (Dediu, Mircea); Ramlau, R (Ramlau, Rodryg); Galiulin, R (Galiulin, Rinat); Balint, B (Balint, Beatrix); Losonczy, G (Losonczy, Gyorgy); Kazarnowicz, A (Kazarnowicz, Andrzej); Park, K (Park, Keunchil); Schumann, C (Schumann, Christian); Reck, M (Reck, Martin); Paz-Ares, L (Paz-Ares, Luis); Depenbrock, H (Depenbrock, Henrik); Nanda, S (Nanda, Shivani); Kruljac-Letunic, A (Kruljac-Letunic, Anamarija); Socinski, MA (Socinski, Mark A.).  
JOURNAL OF CLINICAL ONCOLOGY 2014; 32: Supplement: S; Abstract: 8008

4. Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs).  
Von Pawel, J (Von Pawel, Joachim); Tseng, J (Tseng, Jennifer); Dediu, M (Dediu, Mircea); Schumann, C (Schumann, Christian); Moritz, B (Moritz, Berta); Mendell-Harary, J (Mendell-Harary, Jeanne); Jin, XP (Jin, Xiaoping); Feng, WQ (Feng, Wenqin); Copigneaux, C (Copigneaux, Catherine); Beckman, RA (Beckman, Robert A.)  
JOURNAL OF CLINICAL ONCOLOGY 2014; 32; Supplement: S; Abstract: 8045
5. Quality of life (QOL), and supportive care results : necitumumab phase 3 Squire trial  
Reck M, Socinski MA, Luft A, Szczesna A, Dediu M, Ramlau G, Losonczy G, Molinier O, Schumann C.  
Ann Oncol 2014; 25(suppl4):iv 445. 1267P
6. Scagliotti GV, San Antonio B, Manegold C, Thomas M, Dediu M et al.: Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after completing at least 4 cycles of pemetrexed plus cisplatin induction treatment: a cross-trial analysis of two phase III trials (ID 2449)  
JOURNAL OF THORACIC ONCOLOGY Volume: 8 Supplement: 2 Pages: S877-S878 Meeting Abstract: P2.10-037 Published: NOV 2013
7. De Marinis F, Gridelli C, Dediu M et. al. Palliative radiation during pemetrexed plus cisplatin first-line treatment or pemetrexed continuation maintenance treatment in advanced nonsquamous non-small cell lung cancer (NSCLC): A report of patient safety in the PARAMOUNT trial.  
JOURNAL OF THORACIC ONCOLOGY Volume: 8 Supplement: 2 Pages: S842-S843 Meeting Abstract: P2.08-019 Published: NOV 2013
8. Overall survival (OS) of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC): final results of a phase III study (PARAMOUNT)  
By:Laack, E (Laack, E.)[ 1 ] ; Reck, M (Reck, M.)[ 2 ] ; Schumann, C (Schumann, C.)[ 3 ] ; Eschbach, C (Eschbach, C.)[ 4 ] ; Kimmich, M (Kimmich, M.)[ 5 ] ; Brandts, C (Brandts, C.)[ 6 ] ; Paz-Ares, LG (Paz-Ares, L. G.)[ 7 ] ; De Marinis, F (De Marinis, F.)[ 8 ] ; Dediu, M (Dediu, M.)[ 9 ] ; Pujol, JL (Pujol, J.-L.)[ 10 ] ; Bidoli, P (Bidoli, P.)[ 11 ] ; Molinier, O (Molinier, O.)[ 12 ] ; Sahoo, TP (Sahoo, T. P.)[ 13 ] ; Corral, J (Corral, J.)[ 14 ] ; Melemed, SA (Melemed, S. A.)[ 14 ] ; John, WJ (John, W. J.)[ 14 ] ; Chouaki, N (Chouaki, N.)[ 15 ] ; Zimmermann, AH (Zimmermann, A. H.)[ 14 ] ; Visseren-Grul, CM (Visseren-Grul, C. M.)[ 16 ] ; Leschinger, MI (Leschinger, M., I)[ 17 ] ; Thomas, M (Thomas, M.)[ 18 ]  
ONKOLOGIE 2012; Volume: 35 Pages: 36-37 Supplement: 6
9. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).  
Luis Paz-Ares, Filippo De Marinis, Mircea Dediu, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Oliver Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck, Jesus Corral Jaime, Symantha Melemed, William J. John, Nadia Chouaki, Annamaria Zimmermann, Carla Visseren-Grul, Cesare Gridelli. J Clin Oncol 30, 2012 (suppl; abstr LBA7507)
10. Updated safety and quality of life results of PARAMOUNT study : maintenance pemetrexed (PEM) plus best supportive care (BSC) vs placebo plus BSC immediately following induction treatment with PEM plus cisplatin (CP) for advanced nonsquamous non small cell lung cancer.

CM Visseren-Grul, L. Paz-Ares, **M. Dediu** M. Thomas, P. Bidolli, J. Corral, N. Chouaki , A. Zimmermann, J-L Pujol, C. Gridelli. ESMO congress, Vienna , oc 2012, 1275P. Ann Oncol 2012; 23 suppl 9: 418-419

11. Maintenance pemetrexed (pem) plus best supportive care (bsc) versus placebo plus bsc after pem plus cisplatin for advanced nonsquamous nscl. C. K. Obasaju, L. G. Paz-Ares, F. De Marinis, **M. Dediu**, M. Thomas, . L. Pujol, P. Bidoli, O. Molinier, T. P. Sahoo, E. Laack, M. Reck, J. Corral, S. A. Melemed, W. J. Joh N. Couaki, A. Zimmermann, C. M. Visseren-Grul and C. Gridelli. Ann Oncol 2012; 23 (Suppl 11): xi6-xi8
  
12. Herald: A Phase 1B/2 Trial Of Her3 Inhibitor U3-1287 In Combination With Erlotinib In Patients With Advanced Nonsmall Cell Lung Canceherald: A Phase 1B/2 Trial Of Her3 Inhibitor U3-1287 In Combination With Erlotinib In Patients With Advanced Nonsmall Cell Lung Cancer (NSCLC)  
Von Pawel, Joachim; Tseng, Jennifer; **Dediu, Mircea**; et al.  
Journal of Thoracic Oncology 2012; 7:S119-S120
  
13. First line chemotherapy with pemetrexed plus cisplatin in advanced nonsquamous non-small cell lung cancer(NSCLC): a comparison of two phase III trials.  
Scagliotti G, Gridelli C, De Marinis F, Thomas M, Dediu M, Pujol J, Manegold C, melemed S, John W, Zimmermann A, Chouaki N, Melemed A, Visseren- Grul C, Paz Ares L. J Thorac Oncol 2011; 6: S1160 ( abstr P.3007)
  
14. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).  
L. G. Paz-Ares, F. De Marinis, **M. Dediu**, M. Thomas, J. Pujol, P. Bidoli, O. Molinier, T. P. Sahoo, E. Laack, M. Reck, J. Corral, S. A. Melemed, W. J. John, N. Chouaki, A. Zimmerman, C. M. Visseren Grul, C. Gridelli. J Clin Oncol 29: 2011 (suppl; abstr CRA7510)
  
15. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).  
G. Scagliotti, I. Vynnychenko, Y. Ichinose, K. Park, K. Kubota, F. H. Blackhall, R. Pirker, R. Galiulin, T. Ciuleanu, O. Sydorenko, **M. Dediu**, Z. Papai-Szekely, N. Martinez Banaclocha, S. McCoy, B. Yao, Y. Hei, D. R. Spigel. J Clin Oncol 29: 2011 (suppl; abstr LBA7512)
  
16. MONET 1-AN INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF MOTESANIB IN COMBINATION WITH CARBOPLATIN/PACLITAXEL IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER (NSCLC)  
Scagliotti, G (Scagliotti, Giorgio)[ 1 ] ; Vynnychenko, I (Vynnychenko, Ihor)[ 2 ] ; Ichinose, Y (Ichinose, Yukito); Park, K (Park, Keunchil)[ 3 ] ; Kubota, K (Kubota, Kaoru)[ 4 ] ; Blackhall, F (Blackhall, Fiona); Pirker, R (Pirker, Robert)[ 5 ] ; Popovych, O (Popovych, Oleksandr)[ 6 ] ; Galiulin, R (Galiulin, Rinat)[ 7 ] ; Ciuleanu, TE (Ciuleanu, Tudor-Eliade)[ 8 ] ; Sydorenko, O (Sydorenko, Oleksandr)[ 9 ] ; Dediu, M (Dediu, Mircea); Papai-Szekely, Z (Papai-Szekely, Zsolt); Banaclocha, NM (Martinez Banaclocha, Natividad)[ 10 ] ; Mccoy, S (Mccoy, Sheryl)[ 11 ] ; Yao, B (Yao, Bin)[ 11 ] ; Hei, YJ (Hei, Yong-Jiang)[ 12 ] ; Spigel, DR (Spigel, David R.)[ 13,14 ]

17. A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC. J. Von Pawel, J. H. Harvey, D. R. Spigel, **M. Dediu**, M. Reck, C. L. Cebotaru, E. Kumm, G. Gallant, N. Fox, D. R. Camidge. J Clin Oncol 2010; 28:7s( suppl LBA 7501)
18. Impact of adjuvant chemotherapy in stage IB non-small cell lung cancer. An analysis of 112 consecutively treated patients. **M. Dediu**, O. Ion, R. Ion, A. Alexandru, D. Medin, C. Gal, M. Gongu. J Thorac Oncol 2010; 5:S69( 175PD)
19. Overall survival [OS] results of NCIC Clinical Trials Group [CTG] BR.24: a randomized, double-blind trial of carboplatin plus paclitaxel [C plus P] with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer [NSCLC] Laurie, SA (Laurie, Scott A.)[ 1 ] ; Arnold, A (Arnold, Andrew)[ 1 ] ; Shepherd, FA (Shepherd, Frances A.)[ 1 ] ; Dediu, M (Dediu, Mircea)[ 1 ] ; Ciuleanu, T (Ciuleanu, Tudor)[ 1 ] ; Fenton, D (Fenton, David)[ 1 ] ; Zukin, M (Zukin, Mauro)[ 1 ] ; Goss, G (Goss, Glenwood)[ 1 ] ; Ding, K (Ding, Keyue)[ 1 ] ; Seymour, L (Seymour, Lesley) JOURNAL OF THORACIC ONCOLOGY 2009; Volume: 4 Issue: 9 Pages: S353-S353
20. Cost-effectiveness analysis of erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC) in Romania. Ciuleanu, T. E.; Dediu, M.; Minea, L. N.; et al.VALUE IN HEALTH 2010; 13 Issue: 3 Pages: A38- A38 DOI: 10.1016/S1098-3015(10)72166-5
21. Randomized, double-blind phase ii trial of carboplatin 1 paclitaxel [c1p] with either daily oral cediranib, an inhibitor of vascular endothelial growth factor receptor [vegfr] tyrosine kinases, or placebo, in advanced nonsmall cell lung cancer [nslc]: a study of the national cancer Institute of Canada Clinical Trials Group S.A. Laurie, A. Arnold, F.A. Shepherd, **M. Dediu**, T. Ciuleanu, D. Fenton, M. Zukin, G. Goss, K. Ding, L. Seymour. Ann Oncol 2008; 19 (Suppl. 8) viii90-viii91 (Abstract 231PD)
22. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer. Results of a prospective observational study. **M. Dediu**, E Crsan, M.Radut, A.Tarlea, D. Median, A. Alexandru, G. Vremes, C. Gal. J Thorac Oncol 2008; 3: S63( 169PD)
23. Prognostic value of atelectasis for locally advanced non-small cell lung cancer(NSCLC). **M.Dediu**, D. Median, R. Anghel, C. Gal, A. Alexandru. J Thorac Oncol 2007; 2 : S524 ( # P2-084)
24. Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). Rolski J, Ramlau R, **Dediu M**, et al. J Clin Oncol 2006; 24 ( 18S): 471s (PD- abstr #8513)
25. Phase II trial of the neurokinin-1 antagonist casopitant mesylate for the prevention of chemotherapy-induced nausea/vomiting (CINV) in cancer patients (PTS) receiving highly

- emetogenic chemotherapy (HEC): Subgroup analysis by cisplatin dose  
 Rolski, J (Rolski, Janusz); Ramlau, R (Ramlau, Rodryg); Dediu, M (Dediu, Mircea);  
 Witman, PA (Witman, Philip A.); Bandekar, RR (Bandekar, Rajesh R.); Russo, M (Russo,  
 Mark)  
 ANNALS OF ONCOLOGY 2006; Volume: 17 Pages: 302-302 Supplement: 9
26. Patient outcome following adjuvant chemotherapy (CT) in completely resected stage I-III B, non-small cell lung cancer (NSCLC)  
**M. Dediu**, T. Horvat, R. Anghel, A. Alexandru, D. Median, et al Lung cancer, 2006 ;  
 52 ( Suppl 2) : S20 (abstr O.8).
  27. Atelectasis as a good prognostic factor for advanced non-small cell lung cancer (NSCLC)  
**M. Dediu**, R. Anghel, D. Median, A. Alexandru, D. Nutu, A. Tarlea, A. Silaghi, G.  
 Vremes, C. Gal, L. Nedelus. Ann Oncol 2006; 17 (Suppl 9): ix231-ix232.
  28. Adjuvant chemotherapy(CT) and patient compliance in non-small cell lung cancer (NSCLC). A multivariate analysis of 356 consecutively treated patients.  
**M. Dediu**, A. Alexandru, D. Median Eur J. Cancer 2005;3 : 337 (abstr#1167)
  29. Patients' outcome and pattern of relapses following radical surgery and adjuvant chemotherapy (CT) in non-small cell lung cancer (NSCLC)  
**M. Dediu**, Horvat T, Anghel R, et al. Lung Cancer 2005; 49 (Suppl 2): S96 (abstr PD-089). Abstracts of the 11-th World Conference on Lung Cancer, 3-6 July 2005, Barcelona, Spain
  30. Chemo-radiation dose intensity for patients with locally advanced non-small cell lung cancer (NSCLC), treated with split course radiation and concurrent vinorelbine (NVB) plus cisplatin (CDDP).  
**M. Dediu**, A. Tarlea, A. Alexandru, D. Median, M. Radut. 41-st American Society of Clinical Oncology Annual Meeting, May 13-17, 2005, J Clin Oncol 23 ( suppl 16S), Part I of II, pp :700s, Abstr 7322.
  31. Xyotax/Carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The stellar 3 phase III study.  
 Langer C, O'Byrne K, Ross H, Socinski M, Szczesna A, **Dediu M**, et al. Lung Cancer 2005; 49 (Suppl 2): S36 (abstr O-101). Abstracts of the 11-th World Conference on Lung Cancer, 3-6 July 2005, Barcelona, Spain.
  32. The impact of surgery on the outcome of patients with non-small cell lung cancer (NSCLC) and brain metastasis.  
**M. Dediu**, T. Horvat, A. tarlea, D. Median, A. Alexandru, G. Miron. Annals of Oncology 2004, 15 (Suppl 3): 171 (Abstr 645P).
  33. Non-cytotoxic drug therapy for loco-regional edema and serosal effusion of malignancy.  
 D. Nutu, **M. Dediu**, R. Anghel, D. Spataru, S. Donea, M. Bostina, S. Stan, L. Calustian, A. Constantinescu American Society of Clinical Oncology Annual Meeting Proceedings , Journal of Clinical Oncology 2004, vol 22, No 14 S,pp: 765s( abstr 8145).
  34. Multidrug association for dyspnea related to the neoplastic involvement of the lung.  
 D. Nutu, **M. Dediu**, S. Donea Proc Am Soc clin Oncol ,2003, 22 : 781 (abstr 3138)
  35. Split course radiation with concurrent Vinorelbine (NVB) and Cisplatin (CDDP) in locally advanced Non-Small Cell Lung Cancer (NSCLC). A phase II study  
**M. Dediu**, A. Tarlea, P. Iorga, C. Cornila, P. Bailesteanu, M. Radut. Lung Cancer, Vol 41,

Suppl 2,pp: S238, 2003.

36. Docetaxel plus cisplatin as neoadjuvant chemotherapy for unresectable stage III non-small cell lung cancer (NSCLC) : a comparison of two schedules.  
**M. Dediu**, T. Horvat, A. Tarlea, P. Iorga, M. Radut, I. Cordos, M. Movanu. Proceedings of the American Society of Clinical Oncology ,Vol 21, pp 235b, (abstr 2758), 2002.
37. A comparative evaluation of surgery followed by adjuvant chemo-radiation versus neoadjuvant chemotherapy followed by concurrent chemo-radiation, for stage III A non-small cell lung cancer (NSCLC). A multi institutional study.  
**Mircea Dediu**<sup>1</sup>, Teodor Horvat<sup>2</sup>, Alin Tarlea<sup>1</sup>, Emilia Crisan<sup>3</sup>, Mirela Movanu<sup>1</sup>, Alexandru Nicodin<sup>2</sup>, Polixenia Iorga<sup>1</sup>, Maria Radut<sup>1</sup> Annals of Oncology ( Official Journal of the European Society of Clinical Oncology ), Volume 11, Supplement 4, pp 121, abstract 549 P), 2000.
38. Docetaxel plus cisplatin as neoadjuvant chemotherapy for unresectable stage III Non-Small-Cell Lung Cancer ( NSCLC): A phase II study.  
**M. Dediu**<sup>a</sup>, T. Horvat<sup>b</sup>, A. Tarlea<sup>a</sup>, A. Nicodin<sup>b</sup>, M. Radut<sup>a</sup>, M. Movanu<sup>a</sup>. Lung Cancer ( Journal of the International Association for the Study of Lung Cancer) Vol 29, Suppl 1, pp 113,( abstract 373), 2000.
39. Topotecan (T) and fractionated cisplatin (CDDP) as first line chemotherapy for extensive small cell lung cancer (E-SCLC): A phase I/II study.  
**M. Dediu** , M. Radut, E. Crisan, M. Movanu, P. Iorga.Proceedings of the American Society of Clinical Oncology 19: 2096a,2000 (abstract).
40. High dose cisplatin and concurrent radiation therapy in stage III A non-small cell lung cancer.  
**M. Dediu**,A. Tarlea, R. Anghel, M. Radut, E . Crisan. Annals of Oncology ( Official Journal of the European Society of Clinical Oncology ), Volume 9 ,Supplement 4 , Abstract 428P, P:89,1998.

### ***ABSTRACTS – Other international journals***

41. Adjuvant chemotherapy (CT) for completely resected non-small cell lung cancer (NSCLC). A retrospective analysis of 311 patients.  
**M. Dediu**, T. Horvat, R. Anghel, A. Tarlea, G. Miron, M. Movanu, P.Iorga,C. Cornila, P. Bailesteanu, C. Nistor. Proceeding book of “ The 15-th International Congress on anti-cancer Treatment “, 9-12 February, 2004, Paris- France, pp:229.
42. Neoadjuvant docetaxel and cisplatin for resectable stage III non-small cell lung cancer (NSCLC) : A preliminary analysis.  
**M. Dediu**, T. Horvat, A. Nicodin, M . Radut, M. Movanu. Congressional book of “ The I.A.S.L.C.- W.A.B. Joint International Conference on Lung Cancer and Thoraco-Pulmonology, Genoa,Nov 25-28,1999.

## **Books**

### **1. GUIDELINE FOR DIAGNOSIS AND TREATMENT OF THE LUNG CANCER**

Edited by **Mircea Dediu**

**Contents:** 1.Foreward for the readers. 2.Introduction. 3.Diagnostic and staging of the lung cancer 4.TNM classification. 5.State of the Art for small cell lung cancer. 6.State of the Art for non-small cell lung cancer. 7.Associates treatments for the patient with lung cancer .

Copyright by “ Editura Inedit”. Bucuresti, 1999, ISBN 973-96829-7-9 ; 48 pp

### **2. BRONCHOPULMONARY CANCER.**

Edited by T. Horvat, **M. Dediu**, A. Tarlea.

Contents and Contributors : Forward for the readers; *G. Rosti*. 1.Epidemiology of the lung cancer; *A. Tarlea*. 2. Tumor markers and genetic disorders of the lung cancer; *M. Dediu et al*. 3. Pathology of the lung cancer; *P. Galbenu*. 4. Clinical diagnosis of the lung cancer; *T. Horvat et al*. 5. Imagistic diagnosis of the lung cancer; *C. Zaharia et al*.6.Bronchoscopic evaluation of the lung cancer; *E. Crisan*. 7. Invasive investigations for staging of lung cancer; *I. Cordos et al*. 8. Pathologic examinations for the lung cancer; *P. Galbenu*. 9. TNM classification of lung cancer; *C. Savu et al*. 10. Surgical treatment for the lung cancer; *T. Horvat et al*. 11. Endoscopic treatments for lung cancer; *E. Crisan*. 12. Radiation therapy of the lung cancer; *A. Tarlea*. 13. Chemotherapy for non-small cell lung cancer; *M. Dediu*. 14. Chemotherapy for small cell lung cancer; *M. Dediu*. 15.Combined modality treatment for non-small cell lung cancer; *T. Horvat et al*. 16. Combined modality treatment for small cell lung cancer; *M. Dediu et al*. 17. Lung cancer chemoprevention; *M. Dediu*.

Copyright by “ Editura Universul “ , Bucuresti, 2000. ISBN 973-9027-55-5 ; 392 pp.

### **3. LUNG CANCER. DIAGNOSTIC AND THERAPEUTIC GUIDELINES**

**M. Dediu**, T. Horvat, R. Anghel, A. Tarlea.

Contents: Epidemiology and risk factors. Diagnostic procedures. TNM staging. Therapeutic recommendations for NSCLC : Stage 0, Stage I and II, Stage III, stage IV. Therapeutic recommendations for SCLC: limited stage, extensive stage. Post therapeutic follow up. References.

Copyright by “Editura Universul” , Bucuresti, 2003, ISBN 973-9027-69-5; pp: 49.

### **4. ADJUVANT CHEMO-HORMONAL THERAPY IN BREAST CANCER.**

**A PRACTICAL GUIDELINE.**

**M. Dediu**, R. Anghel.

Contents : 1. Generalities. 2. Classification of patients according to risk factors. 3. Schematic representation of multimodal treatment in mammary carcinoma, stage I, II. 4. Adjuvant chemotherapy. 5. Taxanes in adjuvant treatment. 6. Neoadjuvant chemotherapy. 7. Adjuvant hormonal therapy. 8. Side effects associated with hormonal therapy. 9. Role of aromatase inhibitors as adjuvant hormonal treatment for estrogen receptor positive patients, in post-menopause. 10. Issues of chimio- hormonal association. 11. Chemo with or without hormonal therapy for patients with unknown hormonal receptors. 12. Timing of chemotherapy according to radiation. 12. Conclusions regarding the adjuvant treatment

of breast cancer. Chemotherapy schedules used in adjuvant treatment of breast cancer.  
Copyright by "Editura Universul", Bucuresti, 2004, ISBN 973-9027-79-2;  
pp : 99.

5. New staging system and recent trends in the systemic treatment of the breast cancer  
**M. Dediu**, R. Anghel, D. Nutu, E. Busila, A. Silaghi, S. Donea, M. Iftimie,  
D. Spataru, G. Miron  
Copyright by "Editura DAYA Satu Mare", Satu Mare, 2005,  
ISBN 973- 7756- 04-5; pp : 285

## **PARTICIPANT AUTHOR**

1. TREATMENT OF TUMOR RELAPSES WITH NEW AGENTS IN SMALL CELL LUNG CANCER  
**M. Dediu**  
  
**2<sup>nd</sup> Balkan Congress of Oncology,( Izmir-Turkey – September 10-14 1998)** pp:277-280  
  
Editor George Antypas (President of BUON), Copyright 1998 by MONDUZZI EDITORE S.p.A. International Proceedings Division, Bologna, Italy.
2. BRONCHOPULMONARY CARCINOMA  
T. Ciuleanu, **M. Dediu**, N. Ghilezan ,  
  
in Practical Guidelines in Medicine, edited by Romanian Physicians Collegium, 2001, pp 77-101. ISBN : 973-9394-32-9, 073-9394-69-8.
3. CHEMOTHERAPY OF SUPERIOR VENA CAVA SYNDROME  
**M. Dediu**  
, in T. Horvat, A. Cornea: The Superior Vena Cava Syndrome, Editura Universul 2003, pp :145-160. ISBN 973-9027-75-X.
4. Patient outcome following adjuvant chemotherapy (CT) in completely resected stage I-IIIB, non-small cell lung cancer (NSCLC)  
**M. Dediu**, T. Horvat, R. Anghel, A Tarlea, A. Alexandru, D. Median, C Nistor, A Ciuche, C Savu and P. Iorga.. in Zatloukal P, Petruzelka L editors, International Proceedings of the 10<sup>th</sup> Central European Lung Cancer Conference, Monduzzi Editore ISBN 88-7587-250-3, Bologna, 2006; 31-36.
5. Chemotherapy for resectable non-small cell lung cancer: It's time for a change in the current paradigm  
Mircea Dediu, Aurelia Alexandru, Dragos Median, Georgeta Vremes  
in Lung cancer current status and perspectives 2005; pp:61-89 ISSN: 1107-0625



27.02.2025